看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
, r I/ L* D; I2 L: s
1 ?" { p% j3 F# {) h- S
0 I" m4 {9 L6 H2 TCurrently available feasibility data for possible combination strategies. f1 v& e. A3 x& l0 I$ `, J
————————————————————————————————3 b+ ?4 i8 q3 V9 R" i2 g
Combination Feasibility according to preliminary data # g" o k, d# @. c$ x
——————————————————————————————————
2 ]3 P3 n6 f* M9 L) k* h+ p& fBevacizumab + sorafenib Yes, reduced dose
" ]; ^* @( N; Z* T7 H; \$ xBevacizumab + sunitinib† No
" X8 D! X. B7 c2 a/ i; `$ b1 PBevacizumab + temsirolimus Yes 0 O5 l8 D H; t( \( ^
Bevacizumab + everolimus Yes
" h) |0 R8 z+ \- \Sorafenib + sunitinib ?
0 e$ a7 N) g5 P1 J- u1 vSorafenib + temsirolimus Yes, reduced dose # C }4 {+ [4 T
Sorafenib + everolimus Yes, reduced dose
- V( U: r5 k! LSunitinib + temsirolimus† No
% |' H3 ?: d5 _6 x! ?4 i# {5 I' KSunitinib + everolimus ?
, j. S3 d+ W6 f) G/ F: |Temsirolimus + everolimus ?
, G4 ~# b; Z9 l8 S+ c6 `————————————————————9 c3 \4 X5 P; C9 F1 I( B# k
†Led to US FDA warning.
9 l! u+ K$ M: [5 [+ T" |. U; C?: As yet unattempted combination. r3 r4 P% s- H0 d
|